

# Contents

1. Introduction	1
2. Guidelines for establishing a national programme for essential drugs	2
3. Criteria for the selection of essential drugs	4
4. Guidelines for the selection of pharmaceutical dosage forms	5
5. Quality assurance	6
5.1 WHO's Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	6
5.2 Bioavailability	7
5.3 <i>The international pharmacopoeia</i>	7
5.4 Counterfeit drugs	8
6. Reserve anti-infective agents and monitoring of resistance	9
6.1 Need for surveillance of resistance	9
6.2 Reserve antimicrobials	10
7. Applications of the essential drugs concept	13
8. Essential drugs and primary health care	14
8.1 Existing systems of medicine	14
8.2 The national health infrastructure	14
8.3 The pattern of endemic disease	15
8.4 Supplies	15
8.5 Medicinal drug promotion	15
9. Drug donations	15
10. Post-registration drug studies	15
11. Research and development	18
11.1 Pharmaceutical aspects	18
11.2 Clinical and epidemiological aspects	18
11.3 Educational aspects	19
12. Nomenclature	19
13. Drug information and educational activities	20
14. Selection and updating of lists of essential drugs	23
15. Model List of Essential Drugs (tenth list)	24
16. Considerations and changes made in revising the model list	57
17. Glossary of terms used in the report	67

18. Alphabetical list of essential drugs	69
Acknowledgement	73
References	73
Annex 1	
Application form for inclusion in the Model List of Essential Drugs	77